Thus, combination treatments that not only target oncogenic FLT3, but also its downstream signaling, such as the MAPK, PI3K and STAT5 pathways, may afford improved therapeutic responses in AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.